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Objective To delineate a novel autosomal recessive multiple congenital anomaly-mental retardation
(MCA-MR) syndrome in 2 female siblings of a consanguineous pedigree and to identify the disease-causing
mutation.
Study design Both siblings were clinically characterized and homozygosity mapping and sequencing
of candidate genes were applied. The contribution of nonsense-mediated messenger RNA (mRNA) decay
to the expression of mutant mRNA in fibroblasts of a healthy carrier and a control was studied by pyrose-
quencing.
ResultsWe identified the first homozygous SALL1mutation, c.3160C > T (p.R1054*), in 2 female siblings present-
ing with multiple congenital anomalies, central nervous system defects, cortical blindness, and absence of psycho-
motor development (ie, a novel recognizable, autosomal recessiveMCA-MR). Themutant SALL1 transcript partially
undergoes nonsense-mediated mRNA decay and is present at 43% of the normal transcript level in the fibroblasts
of a healthy carrier.
Conclusion Previously heterozygous SALL1 mutations and deletions have been associated with dominantly in-
herited anal-renal-radial-ear developmental anomalies. We identified an allelic recessive SALL1-related MCA-MR.
Our findings imply that quantity and quality ofSALL1 transcript are important for SALL1 function and determine phe-
notype, and mode of inheritance, of allelic SALL1-related disorders. This novel MCA-MR emphasizes SALL1 func-
tion as critical for normal central nervous system development and warrants a detailed neurologic investigation in all
individuals with SALL1 mutations. (J Pediatr 2013;162:612-7).
S
ALL1, a multiple zinc finger transcription factor of 1324 amino acids, is a key mediator of developmental pathways
during organogenesis and cell differentiation. SALL1 regulation and SALL1 protein function are incompletely under-
stood.1,2 Heterozygous early-truncating SALL1 mutations are known to cause autosomal dominant Townes–Brocks
syndrome (TBS, MIM #107480), a malformation syndrome without severe central nervous system (CNS) involvement.3,4
Such mutations result in truncated proteins thought to act by dominant negative effects.5,6 SALL1 haplo-insufficiency7 and
late-truncating mutations which partially undergo nonsense-mediated mRNA decay (NMD) cause mild TBS,5,7,8 suggesting
distinct pathophysiological mechanisms of SALL1 mutations.
We identified 2 female sibling, born to healthy consanguineous parents, affected by a multiple congenital anomaly-mental
retardation (MCA-MR) syndrome with absence of psychomotor development caused by the first identified homozygous
SALL1 mutation c.3160C > T (p.R1054*). The mutation leads to a reduced amount of transcript encoding a late-
truncated SALL1. Our results indicate that quantity and quality of residual SALL1 transcript determine the phenotype
and the mode of inheritance of the 2 allelic disorders, TBS and this MCA-
MR, and imply SALL1 function as critical for human CNS development.From the 1Department of Pediatrics and Adolescent
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In the second pregnancy of a consanguineous Turkish
couple, the fetus was diagnosed with corpus callosum
hypoplasia and tetralogy of Fallot (TOF) by fetal ultra-
sound at 21 + 1 weeks, and fetal magnetic resonance
imaging revealed oligohydramnios and CNS abnormalities
(Figure 1). Diagnosis of a MCA-MR syndrome without
further classification was made, and the parents opted for
termination of the pregnancy at 22 + 2 weeks. The female
fetus’s weight was 515 g (10th percentile), crown-heel
length 30 cm (50th percentile), and head circumference
19 cm (50th percentile). There were contractures of upper
and lower limbs and bilateral ear and limb malformations
(Figure 1). Autopsy additionally showed bilateral hypo-
plastic multicystic kidneys.
Patient 2
Patient 2 was the female sibling of patient 1. Fetal ultrasound
disclosed a ventricular septal defect at 19 + 5 weeks; hypoplas-
tic kidneys and oligohydramnios later progressing to anhy-
dramnios were noted at 21 weeks. Fetal magnetic resonanceFigure 1. A-F,Clinicalmanifestation andG-L,CNSabnormalities
D-F, I, J, patient 2. Note B, E, F, limb malformations consisting o
hand, and incomplete preaxial polydactyly on the right hand in both
in patient 1.G,H, T2-weighted fast spin-echo sequences in corona
control fetus, each at 21 weeks of pregnancy. Both affected fetuse
tricles, and hyperintense T2-weighted signal changes in the regioimaging at 21 + 1 and 23 + 5 weeks showed hexadactyly of
the left hand and CNS abnormalities identical to patient 1
(Figure 1). Abnormal fetal movement patterns were noted.
The patient was born at term with Apgar scores 4/6/9,
weight 3570 g (50th-70th percentile), length 52 cm (50th-
70th percentile), and head circumference 35.5 cm (50th-75th
percentile). She presented at birth with TOF, atrial septal
defect, imperforate anus with perianal fistula, bilateral
hypoplastic multicystic kidneys with chronic renal failure,
generalized muscular hypotonia, and ear and hand
malformations. Respiratory distress and lung hypoplasia
secondary to oligohydramnios required intubation for 48
hours after birth. Chronic renal failure progressed to end-
stage kidney disease, requiring dialysis from 7 months of
age. Hypotonia and insufficient central coordination
required permanent tube feeding. At 6 months of age, TOF
was corrected by surgery. Left-sided sensorineural hearing
loss and right-sided deafness, respectively, were diagnosed by
brainstem audiometry. Ophthalmologic investigations at
birth, 3, and 6 months of age revealed absent visual fixation
without any structural eye abnormalities, indicating corticalin fetal magnetic resonance imaging inA-C,G,H, patient 1 and
f bilateral triphalangeal thumbs, extra preaxial digit on the left
patients andC,bilateral cutaneous I/II and III/IV toe syndactyly
l and axial planes of patient 1, I, J, patient 2, andK, L, a healthy
s present with hypoplastic corpus callosum, asymmetric ven-
n of the triangular crossroads (arrows in G-J).
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she showednohead control, wasnot able to roll over or sit, and
showed no social interaction. The patient died at 19months of
age because of bacteremia. Normal karyotypes were obtained
in both patients.
Clinical Investigations in Carriers
Eleven mutation carriers were investigated for dysmorphism,
congenital anomalies, and heart sounds, with emphasis on
minor TBS features. All were healthy except for a ventricular
septal defect in the father of both patients described here, re-
quiring no treatment. In both parents renal ultrasound, skel-
etal radiographs, and hearing tests were normal. Renal
function was normal in both parents and 5 additional disease
mutation carriers. One further carrier was not available for
clinical investigation but was reported to be healthy. There
was no family history of anal atresia, hearing loss, or impaired
renal function.
DNA Analysis, Linkage Analysis, and SALL1
Sequencing
DNAwas extracted from tissue sections of patient 1 and from
blood or buccal smear samples of all other participants. For
linkage analysis, 2 affected and 10 unaffected relatives were
genotyped with Illumina Hap370 single nucleotide polymor-
phism arrays (Illumina, Little Chesterford, United King-
dom). GeneChip hybridizations and respective processing
steps were performed according to the manufacturer’s in-
structions by a professional GeneChip service provider (Mi-
croarray Facility T€ubingen, Medical Genetics Department,
T€ubingen, Germany). Multipoint logarithm of the odds
scores and haplotypes were obtained with the ALLEGRO
program9 under the hypothesis of an autosomal-recessive,
fully penetrant mutation, inherited identical-by-descent (ho-
mozygosity mapping). The SALL1 coding regions and splice
sites were polymerase chain reaction amplified and directly
sequenced in patient 2. All family members were tested for
the presence of the c.3160C > T mutation detected in patient
2. For SALL1 sequencing primer sequences were based on the
National Center for Biotechnology Information reference en-
tries for messenger RNA (NM_002968) and genomic DNA of
SALL1 (NG_007990.1). Primers and conditions are available
from the authors on request.
RNA Extraction, Cyclohexamide Treatment, and
Pyrosequencing
The expression level of mutant relative to wild-type allele,
with or without exposure to cycloheximide, was quantified
in fibroblast complementary DNA (cDNA) from a heterozy-
gote by pyrosequencing.5 A positive control experiment was
conducted in parallel on fibroblasts heterozygous for the
SALL1 mutation 3414_3415delAT, which was previously
shown to undergo NMD.5 Cells were rinsed in sterile phos-
phate buffered saline (Invitrogen, Paisley, United Kingdom),
stored at70C in 1 mL of TRIzol (Invitrogen) and RNA ex-
tracted according to the manufacturer’s protocol. Three mi-
crograms of RNA were used for cDNA synthesis, using614random hexamer primers, according to the manufacturer’s
instructions (RevertAid Premium First Strand cDNA Synthe-
sis Kit; Fermentas, York, United Kingdom).
Pyrosequencing was carried out on a PSQ-HS96A instru-
ment (Biotage, YstradMynach, United Kingdom) to quantify
the expression level of mutant allele relative to wild-type al-
lele, with orwithout exposure to cyclohexamide as described.5
Hemi-nested touchdown polymerase chain reaction was used
to avoid concurrent amplification of the X chromosomal
SALL1P, starting with primers spanning intron 2-3 (forward
primer 50-ACACTGCTTGTGACATTTGTGGCAAAAC-30,
reverse primer 50-TAGAAATGTCATGGGGCCATCCACAG
AGAGC-30) for 16 touchdown cylces (70C-62C), followed
by 25 cycles at 62C using the above forward primer and the
reverse 50-B-ACGAAGCCGTTGACCTCTGTCTTGATGA-
30. The pyrosequencing primer was: 50-ACATGTTGACA
CATCAGAT-30, using the dispensation order: G-T-G-A-T-
G-A-C-G-A-C-G-A-T-C-G to compare the mutant/wild-
type peaks G3/G9, A4/A10, G6/G12, A7/A13.
The proportion of mutant allele (mutant/wild-type, cor-
rected for background) was first calculated in replicate con-
trol samples (genomic DNA from individuals with normal
[CC], heterozygous [CT] or homozygous mutant [TT]) ge-
notypes at position 3160 of SALL1. The peak comparison
G3/G9 was discarded as it showed a higher standard deviation
than the other measurements. Quadratic equations to fit cal-
ibration curves for each of the other peak comparisons were
individually calculated and the estimated proportions of mu-
tant allele ascertained by obtaining the means of these calcu-
lated figures from 3 replicate experiments.
Results
We delineate a novel, autosomal recessive MCA-MR, charac-
terized by TOF, polycystic hypoplastic kidneys with prenatal
onset of chronic renal failure, limb and ear malformations,
sensorineural deafness, corpus callosum hypoplasia, cortical
blindness, and complete lack of psychomotor development
(Figure 1), already manifesting prenatally as an abnormal
fetal movement pattern. Homozygosity mapping in this
consanguineous family (Figure 2, A) revealed a maximal
logarithm of the odds score of 1.9 within 5 homozygous
intervals located on chromosomes 2, 9, and 16 (data not
shown). We selected SALL1 from the largest candidate
region for mutation analysis on the basis of partial clinical
overlap with TBS, known function and expression patterns.
Sequencing identified a homozygous SALL1 mutation,
c.3160C > T (p.R1054*), in both affected siblings that
segregates with the disease (Figure 2, B). Twelve healthy
family members were carriers of this mutation. This novel
mutation leads to a premature stop codon in exon 2 and
was expected to trigger NMD. Pyrosequencing showed that
the mutant transcript was present at 43% of the level of the
normal transcript in carrier fibroblasts; this increased to
68% after cycloheximide treatment, indicating a partial
contribution of NMD to the relative deficiency of mutant
transcript (Figure 2, C). The SALL1 protein encoded by theVodopiutz et al
Figure 2. A, Simplified pedigree showing multiple consan-
guinity loops, CNS-TBS patients represented by filled black
circles. For privacyprotection carriers are not indicated.B,Se-
quencing chromatograms from a patient (top) and a control
(bottom). The c.3160C > T mutation is indicated by an arrow-
head.C,Relative quantification by pyrosequencing of themu-
tant versus the wild-type allele in SALL1 cDNA from carrier
fibroblasts, before and after treatment by cycloheximide.
March 2013 ORIGINAL ARTICLESmutant transcript lacks 270 C-terminal residues including the
last double zinc finger domain and a beta-catenin binding
domain (Figure 3).1
Discussion
The condition we describe here, tentatively termed central
nervous system-Townes-Brocks syndrome (CNS-TBS), is
distinguished from TBS by prenatal onset of chronic renal
failure, severe CNS involvement, and autosomal recessive in-
heritance. Corpus callosum hypoplasia is rare in TBS, the
majority of TBS patients have normal intelligence, and pro-
found mental retardation has not been reported in
TBS.4,10,11 A search of published reports in Medline, Online
Mendelian Inheritance in Men, the London Dysmorphology,
and the POSSUM Databases did not reveal any known syn-
dromes resembling the pattern of findings in our patients.
We conclude that CNS-TBS represents a distinct clinical en-
tity, which is supported by the demonstration of a previously
not described genetic cause in our patients, a novel and ho-
mozygous (p.R1054*) SALL1 mutation.
We show that the mutant transcript partially undergoes
NMD, suggesting that a decreased amount of mutant protein
is produced. The residual transcript is expected to result inHomozygous SALL1 Mutation Causes a Novel Multiple Congenita late-truncated protein. Together, the decreased amount
and supposedly limited functionality of SALL1 protein ini-
tially imply loss-of-function as the disease mechanism in
CNS-TBS. However, complete loss-of-function of 1 SALL1
allele (ie, haplo-insufficiency resulting from whole gene dele-
tions) already causes mild TBS phenotypes, as emerged from
the observation of few patients with such deletions.7 Interest-
ingly, no TBS features were present in any of 12 heterozygotes
for p.R1054* from the extended pedigree. This observation
supports the idea that some protein is produced from the
mutant allele. Furthermore, this observation supports the
idea that the truncated protein resulting from p.R1054*,
thus, must preserve some degree of SALL1 function, appar-
ently sufficient to prevent heterozygotes from TBS features.
However, the residual SALL1 function resulting from the
p.R1054* mutation is not sufficient to prevent homozygotes
for this mutation from having disease; homozygotes for this
mutation are supposed to produce less functional SALL1
protein than individuals with only 1 copy of SALL1, as they
are much more severely affected. In addition, the truncated
p.R1054* protein does not seem to exert overt dominant-
negative effects in p.R1054* heterozygotes. In contrast,
a mild TBS phenotype is observed in patients with reported
coding mutations just 30 of the p.R1054* mutation in
SALL1. Three of these mutations represent frameshifting-
truncating mutations that remove the same 2 protein do-
mains as the p.R1054* mutation does.10 A comparable
reduction in transcript level was found for 1 of these muta-
tions (c.3414_3415delAT, p.C1139Wfs*14).5,8,10 We hypoth-
esize that mild TBS symptoms in these patients likely arise by
qualitative, dominant-negative effects of such truncated pro-
teins. We hypothesize that the distinctly abnormal C-termini
of residual SALL1 proteins determine any dominant-negative
effects, comparable with the example of distinct phenotypic
outcome associated with receptor tyrosine kinase ROR2mu-
tations.12 The presence or absence of such effects might be
determined by degree of NMD, protein stability, and nuclear
and cytoplasmic distribution of different truncated mutant
isoforms of SALL1 (Figure 3). In summary, we conclude
that heterozygotes for the p.R1054* SALL1 mutation are
unaffected as the truncated p.R1054* protein preserves
some degree of residual SALL1 function and does not exert
overt dominant-negative effects, both sufficient to prevent
p.R1054* heterozygotes from TBS features. We consider
the ventricular septal defect in 1 carrier for CNS-TBS to be
unrelated to his being heterozygous for the p.R1054*
SALL1 mutation, as it is represents an isolated, mild defect,
and such heart defects are very common in the general
population; however, we cannot exclude that this
ventricular septal defect represents a mild phenotype with
incomplete penetrance of this late-truncating SALL1
mutation.
The balance between quantity and quality of wild-type and
truncated SALL1 protein suggests a model in which the phe-
notypic outcome of SALL1-related disorders is determined
by an integration of loss-of-function and dominant negative
effects. This model accounts for classical TBS, in which early-al Anomaly—Mental Retardation Syndrome 615
Figure 3. A, Schematic of SALL1 protein, localization of known mutations and the best characterized SALL1 interaction
domains: SALL1 (1324 aa) harbors 10 zinc finger domains (black boxes) and heterochromatin (*), beta-catenin (#), and
SALL1,2,3,4 (+) binding sites. In TBS all previously reported mutations are heterozygous truncating mutations (arrows). The ma-
jority of mutations cluster in a hot spot region and result in 50-truncation, but late 30-truncatingmutations and heterozygous whole
gene deletions are also described inmild TBS. CNS-TBS is caused by a novel homozygous late 30-truncatingmutation p.R1054*.
B, Amount of wild-type (white) and truncated (gray) SALL1 protein in relation to phenotypic expression in humans. In the pre-
sented model the remaining transcript is assumed to represent the level of protein. Healthy subjects express 50% of the
wild-type SALL1 protein per allele. CNS-TBS patients express 21% 30-truncated SALL1 protein per mutant allele and no
wild-type protein due to homozygous p.R1054* mutation which partially undergoes NMD. CNS-TBS carriers are healthy and ex-
press 50%wild-type SALL1 protein and 21%30-truncated SALL1 protein. All TBS patients express 50%wild-type SALL1 protein
from the wild-type allele. Classical TBS patients express additionally 50% 50-truncated SALL1 protein due to 50-hot spot muta-
tions which escape NMD. There are 3 patients with mild TBS due to haploinsufficiency caused by heterozygous gene deletion.
Patients with mild TBS due to p.C1139Wfs*14 mutation, which partially undergo NMD express additional 22% late-truncated
SALL1 protein.C, SALL1 mouse models corresponding to B, Heterozygous Sall1DZn2-10mice, expressing truncated SALL1 pro-
tein, present with a dominant TBS phenotype including limb defects and hearing loss,14 whereas Sall1/mice present with au-
tosomal recessive isolated bilateral renal agenesis and no phenotype in heterozygotes.13 The phenotype in both CNS-TBS
patients does not correspond to the phenotype in homozygous Sall1/ mice but resembles the more severe phenotype
seen in homozygousSall1DZn2-10mice including renal agenesis (100%), limb defects (57%), anal malformations (>50%), and neu-
ral tube closure defects (38%). WT, wild-type.
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equal levels.5 Through homodimerization of mutant and
wild-type SALL1, a reduction of functional protein at natural
target sites might cause disease by loss-of-function, and addi-
tional dominant-negative effects are mediated by heterodi-
merization with other members of the SALL family.6 The
hypothesis of an integration of loss-of-function and domi-
nant negative effects is supported by Sall1 mouse models.
Homozygous Sall1-deficient mice present with renal agenesis
at birth,13 and heterozygotes are normal. Heterozygous
Sall1DZn2-10 mice, expressing early truncated Sall1, resemble
the classical TBS phenotype and homozygous Sall1DZn2-10
mice are embryonically lethal and present with a severe
TBS phenotype with CNS involvement.6,14 The phenotype
in p.R1054* homozygotes resembles the phenotype of homo-616zygous Sall1DZn2-10 mice. We, therefore, hypothesize that in
p.R1054* homozygotes the truncated protein exerts addi-
tional dominant-negative or gain-of-function effects. The
profound neurologic phenotype in humans and mice with
homozygous expression of truncated SALL1 protein impli-
cates an important function of SALL1 in neurogenesis.15
Functional redundancy of Sall1 and Sall4 in murine neurula-
tion may explain the apparent lack of a CNS phenotype in
Salll1-/- mice16 and heterozygous Sall1DZn2-10 mice. Consid-
ering multiorgan involvement, absence of any psychomotor
development and death in early infancy in p.R1054* homo-
zygotes, CNS-TBS might constitute the most severe viable
SALL1-related phenotype in humans (Figure 3).
Most of the SALL1 mutations reported to-date escape
NMD either completely or partially,5,6 which remainsVodopiutz et al
March 2013 ORIGINAL ARTICLESunexplained. Escaping NMD17 can modify phenotypes con-
veyed by allelic truncating mutations, as demonstrated for
mutations implicated in neurologic disorders in SOX10,18
MPZ,19 and NFIX.20 We observed an unusually low restora-
tion of mutant messenger RNA expression upon protein syn-
thesis inhibition. While this finding remains currently
unexplained, it emphasizes the fact that the classical NMD
mechanism does not apply to most or all SALL1 mutations.
Our results imply that both quantity and quality of resid-
ual transcript might be important for residual SALL1 func-
tion and determine the phenotype and the mode of
inheritance of the 2 allelic disorders TBS and CNS-TBS.
SOX10,18 ROR2,12 and NFIX20 are examples of other genes
in which mutations cause different recessive or dominant
conditions, with partially overlapping phenotypes. CNS in-
volvement in CNS-TBS highlights an essential role of
SALL1 in human neurogenesis and warrants a detailed neu-
rologic investigation in all patients with SALL1 mutations. n
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